一个多中心,双盲,12周,随机,安慰剂对照试验的辅助N-乙半氨酸治疗耐治疗的PTSD
Richard A Kanaan1, Gina Oliver2, Anita Dharan1
1University of Melbourne, Department of Psychiatry, Austin Health, Heidelberg, VIC, Australia.
Psychiatry research
|August 4, 2023
概括
在一项为期12周的试验中,N-乙半氨酸 (NAC) 并没有改善耐治疗的PTSD症状. 然而,在64周的长期随访中,NAC可能会减少物质渴望的持续时间和抵抗力.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 创伤后应激障碍 (PTSD) 可能与氧化应激有关.
- 目前,N-乙半氨酸 (NAC) 正在研究其减轻大脑氧化压力的潜力.
- 这项研究探讨了NAC作为对抗标准治疗的PTSD患者的附加疗法.
研究的目的:
- 评估辅助性N-乙半氨酸 (NAC) 在患有治疗耐药性PTSD的成年人中的疗效.
- 评估NAC对PTSD症状严重程度,抑郁症和物质渴望的影响.
- 确定NAC在这个患者群体中的长期影响.
主要方法:
- 进行了一项多中心,随机,双盲,安慰剂控制的试验.
- 参与者接受了12周的口服NAC (2.7g/天) 或安慰剂.
- 主要结局是临床医生管理的DSM-5 (CAPS-5) PTSD评分尺度在12周的变化;次要结局包括抑郁症和物质渴望,在16周和64周进行随访.
主要成果:
- 在12周后,在NAC和安慰剂组之间没有发现CAPS-5得分或二次结果的显著差异.
- 在105名随机选择的参与者中,有81人完成了为期12周的试验.
- 在64周的随访中,在渴望持续时间和抵抗方面观察到有利于NAC的显著改善.
结论:
- 最初的12周试验显示,辅助NAC与安慰剂相比,对于治疗耐药的PTSD没有益处.
- 这项研究是第一个多中心随机试验,用于治疗耐药性PTSD的辅助NAC.
- 长期随访表明,NAC在减少PTSD患者对物质的渴望方面具有潜在的益处.
相关概念视频
01:27Post-traumatic Stress Disorder
71
Post-traumatic stress disorder (PTSD) is a psychiatric condition that arises following exposure to traumatic events such as natural disasters, forced displacement, or severe accidents. It significantly impairs individuals' ability to cope with daily activities and disrupts their emotional and psychological equilibrium.
Symptoms and Behavioral Manifestations
A spectrum of distressing symptoms characterizes PTSD. Recurrent flashbacks, where individuals involuntarily relive traumatic events,...
Symptoms and Behavioral Manifestations
A spectrum of distressing symptoms characterizes PTSD. Recurrent flashbacks, where individuals involuntarily relive traumatic events,...
71
01:30Electroconvulsive Therapy
69
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
69
01:22Alzheimer's Disease: Treatment
215
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
215